JY
NVLN

Jeff Yass’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Jeff Yass’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-12,454
Closed -$10K – 11210
2019
Q2 		$10K Buy
+12,454
New +$13.9K ﹤0.01% 10081
2019
Q1 		– Sell
-48,476
Closed -$42K – 10402
2018
Q4 		$42K Buy
+48,476
New +$54.8K ﹤0.01% 8539
2018
Q1 		– Sell
-12,007
Closed -$50.9K – 10653
2017
Q4 		$37K Buy
+12,007
New +$57.7K ﹤0.01% 8989

Other funds holding NVLN

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Jeff Yass's NVLN Position: Q3 2019 in Review

Jeff Yass sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2019, closing a stake of 12,454 shares — an estimated $10K sold.

Jeff Yass first reported a position in NVLN in Q4 2017 and held it in 3 quarters. The position peaked at $42K in Q4 2018. 31 funds tracked by Wall St. Rank hold NVLN as of Q3 2019.

  • Jeff Yass reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q3 2019 after selling out during the quarter.
  • Jeff Yass sold 12,454 Novelion Therapeutics Inc. Common Shares shares in Q3 2019, an estimated $10K.
  • Jeff Yass first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2017 and held it in 3 quarters.
  • Jeff Yass's Novelion Therapeutics Inc. Common Shares position peaked at $42K in Q4 2018.
  • 31 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2019.

Based on Susquehanna International Group's 13F filing for Q3 2019, filed 14 Nov 2019.